Key Takeaways
- FY24 EBITDA guidance reaffirmed with conviction: Management expects to reach the previously guided FY24 EBITDA level (1.7–2x) in the next year, driven by capacity ramp-up across all three long-term contracts.
- FY23 is a consolidation year: EBITDA growth guided at high single digits, as the ₹138 crore shortfall fee from the first contract drops off and nitric acid shortages persist through H1.
- Nitric acid is the binding constraint: Supply shortages hit Q4 production and will remain challenging in H1 FY23; a ₹150–200 crore backward-integration plant for concentrating imported weak acid is the structural fix, targeted by end-FY24.
- The second long-term contract is live and ramping fast: Commercial manufacturing began in Q4, ~80% of customer CapEx has been received, and utilisation will be at a very high level from the first year itself.
- What to watch next quarter: The NCLT hearing on the pharma demerger in June 2022, any improvement in nitric acid availability, and the pace of ramp-up at the cancelled first contract’s plant.
The Three-Contract Engine: Ramp-Up & Revenue Conversion
- First contract (cancelled, now merchant): The five-step dichlorobenzene chain is in ramp-up phase; the plant for the cancelled contract is already online and targeting 70–80% utilisation by FY24, with the entire chain reaching ~90% utilisation over the next 2–3 years.
- Second contract: Commercial manufacturing began in Q4 FY22; incremental revenue of over ₹500 crore expected by end-FY23, with utilisation at a very high level from the first year because of how the contract is structured.
- Third contract & NCB expansion: Projects expected on stream in FY23, with ramp-up through FY23 and FY24.
- Capacity utilisation trajectory: Virtually all process blocks are expected to reach 70–90% utilisation by FY24, unlocking the CapEx done over FY19–22 that has not yet fully flowed into revenue or EBITDA.
- Nitrotoluene capacity already reached ~80% utilisation in Q4 FY22, providing one proof point that ramp-up is underway.
Rajendra Gogri: "Significant jump in the next 3 years in EBITDA will happen because by that time our capacity utilization will reach 80-90%."
Nitric Acid: The Bottleneck & The Fix
- Q4 impact: Production and revenue were hit by a supply shortage of key raw material nitric acid; management worked to optimise the product mix to protect profitability.
- Near-term outlook: Availability is expected to remain challenging in H1 FY23, with stabilisation likely in H2 FY23 as new domestic capacity comes online.
- Structural fix: Aarti is setting up a backward-integrated unit to concentrate weak nitric acid (225–250 tpd), tied up with a technology partner, at a cost of ₹150–200 crore, targeted for commercialisation by end-FY24.
- Strategic logic: Concentrated nitric acid cannot be imported into India, but weak nitric acid can; this plant creates a backup supply route by importing weak acid and concentrating it in-house.
- Cost of the backup: Importing weak acid and concentrating it may cost ₹5–10/kg more, but the multiplier effect of non-availability on downstream production is much larger.
- Long-term strategy: A comprehensive nitric acid strategy, potentially including an ammonia-to-weak-nitric-acid plant, is still being developed and expected to be clarified by Q1 FY24.
Rajendra Gogri: "My price may be INR 5-10 higher, but know the multiplier effect for us is much more if the material is not available."
FY23–FY25 Earnings Trajectory
- FY23 EBITDA: High single-digit growth expected, on a base that includes the ₹138 crore shortfall fee from the first contract (which had no associated revenue and will not recur). Management characterises FY23 as a year of consolidation with volume ramp-up across projects.
- FY23 revenue: Expected to grow faster than EBITDA because the shortfall fee that drops off had no revenue component.
- FY24 EBITDA: Management feels they should be able to reach the previously guided FY24 level (1.7 to 2 times) in the next year.
- FY25: Significant jump expected alongside FY24 as the full benefit of high utilisation flows through.
- First contract utilisation in FY23: The cancelled-contract plant will still be at only 35–40% utilisation in FY23, leaving material headroom for FY24.
- Margin outlook: Absolute delta margin was maintained in Q4 despite cost pressures; H1 FY23 may still see nitric-acid-related pressure, with improvement in H2 as domestic supply stabilises.
Rajendra Gogri: "At the EBITDA level, we feel whatever the guidance which we have given on FY24, we should be able to reach those level in next year."
New Chemistry Pipeline & CapEx Deployment
- CapEx commitment: ₹3,000 crore+ by FY24 remains on track; roughly ₹1,500 crore is for existing/running business, with the rest for new products (multipurpose plants) where sales start more from FY25 onwards.
- New product pipeline: 40+ products in specialty chemicals and 50+ in pharma, providing visibility toward the FY27 growth guidance.
- New chemistries: The ~40 specialty chemical products over the next 2–3 years are centred on the chlorotoluene chain and new capabilities: ring chlorination, photo chlorination, AHF fluorination, ammoxidation, and Grignard.
- End-market mix: Pharma and agro will account for ~70–80% of the new product range, with dyes and pigments at ~20%; pharma involves significant import substitution, while agro molecules are growing on strong agri commodity prices.
- Margin profile: Incremental products from new chemistries are expected to carry higher EBITDA-to-sales; if existing is ~20%, the new range could be ~25% or more.
- Plant configuration: New facilities include dedicated-chemistry multi-product plants plus a universal multipurpose plant for more advanced chemistries like Grignard.
- Demand-side resilience: No major demand issues seen from European customers, who produce for global markets; energy-intensive steps are more on Aarti’s side, so European energy cost issues may create competitive opportunities where Aarti competes with European producers.
- Discretionary softness: Some pushback seen on dyes and pigments due to inflation impacting discretionary spends; management is reshuffling product and geographical mix to maintain high capacity utilisation.
Pharma Demerger & Segment Performance
- Pharma segment Q4: 52% revenue growth and 30% EBIT growth YoY, driven by strong volume growth, higher off-take from generic pharma companies, and the Xanthine business.
- Specialty chemicals Q4: EBIT expanded 19% YoY to ₹246 crore, supported by the ability to pass on input cost variations and optimise the product mix to sustain volumes.
- Demerger timeline: The NCLT, Ahmedabad has scheduled the hearing on the pharma demerger application in June 2022; management is hopeful of a favourable approval, with two to three months thereafter for completing formalities, allotment of new shares by Aarti Pharmalabs Ltd, and listing.
- New API facility at Tarapur: In final stages of commissioning, expected to be commercialised in Q1 FY23; total revenue potential of $25–30 million, ramping up over three years, with EBITDA margins in the 17–20% range.
People, Costs & Operating Context
- Talent build-up: Close to 1,500 personnel onboarded in FY22 across functions, including for plants to be commissioned in H1 FY23; hiring is done proactively 5–6 months in advance of requirement.
- Talent strategy: Management sees talent as a key challenge going forward and maintains a dual strategy of a robust internal pipeline and training, plus proactive external hiring to build a cushion.
- Employee cost: Q4 employee cost includes a substantial portion as revenue expenditure; some employees for the third contract are currently in capital WIP, so employee cost will increase in FY23 but a substantial portion was already expensed in Q4.
- Logistics and utilities: Logistic costs generally get passed through because ocean freight increases are difficult to bear; utility costs were already high so on a QoQ basis there was not much change.
- R&D spend: May go up a little in the next 1–2 years from the FY22 range of ₹60–80 crore.
Rajendra Gogri: "One of the key challenges going forward will be how do you manage the talent? So that is why, we like to have some cushion in the talent and also do continuous internal training to upgrade the people."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 EBITDA | Reach previously guided FY24 level (1.7–2x) | Next year (FY23) |
| FY23 EBITDA growth | High single-digit growth (on base including ₹138 crore shortfall fee) | FY23 |
| Second contract revenue | Incremental revenue of over ₹500 crore | By end-FY23 |
| First contract plant utilisation | 70–80% utilisation for the cancelled-contract plant | By FY24 |
| Overall capacity utilisation | Most capacities at 70–90% utilisation | By FY24 |
| CapEx | ₹3,000 crore+ invested | By FY24 |
| Nitric acid concentration plant | Commercialised, capacity 225–250 tpd, cost ₹150–200 crore | By end-FY24 |
| New API facility (Tarapur) | Commercialised | Q1 FY23 |
| Pharma demerger | NCLT hearing, then 2–3 months for formalities and listing | Hearing June 2022 |
| Long-term nitric acid strategy | Comprehensive strategy clarified | By Q1 FY24 |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | ₹2,018 cr, +50% YoY |
| EBITDA | ₹339 cr, +30% YoY; +52% YoY normalising for ₹37 cr shortfall fees in Q4 FY21 |
| EBITDA margin | 16.8% |
| Profit after tax | ₹194 cr, +39% YoY |
| Speciality Chemicals revenue | ₹1,629 cr, +49% YoY |
| Speciality Chemicals EBIT | ₹246 cr, +19% YoY |
| Pharma revenue | ₹388 cr, +52% YoY |
| Pharma EBIT | ₹67 cr, +30% YoY |
| FY23 EBITDA growth guidance | High single digit YoY, on a base including ₹138 cr shortfall fee in FY22 |
| FY24 EBITDA guidance | 1.7x to 2x FY21 EBITDA |
| Nitrochlorobenzene production | 19,551 MT, vs 19,100 MT in Q4 FY21 and 18,504 MT in Q3 FY22 |
| Nitro-Toluene production | 5,155 MT, vs 2,935 MT in Q4 FY21 and 3,633 MT in Q3 FY22 |
| Hydrogenated products production | 3,029 MT, vs 1,935 MT in Q4 FY21 and 2,878 MT in Q3 FY22 |
| CAPEX incurred in Q4 | ₹360 cr; FY22 total CAPEX over ₹1,300 cr |
| Employee additions in FY22 | ~1,500 personnel onboarded; total workforce roughly 8,000-8,500 |